Tigulixostat
- Generic Name
- Tigulixostat
Effect of Tigulixostat on the Pharmacokinetics of Theophylline
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- LG Chem
- Target Recruit Count
- 24
- Registration Number
- NCT06189404
- Locations
- ๐บ๐ธ
PPD - Austin Research Unit, Austin, Texas, United States
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
Phase 3
Recruiting
- Conditions
- GoutHyperuricemiaGout FlareTophi
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- LG Chem
- Target Recruit Count
- 350
- Registration Number
- NCT05586958
- Locations
- ๐บ๐ธ
Meridian Clinical Research, LLC, Portsmouth, Virginia, United States
๐บ๐ธPCCR Solutions, Colleyville, Texas, United States
๐บ๐ธTriad Clinical Trials, Greensboro, North Carolina, United States
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Phase 3
Completed
- Conditions
- HyperuricemiaGoutGout FlareTophi
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- LG Chem
- Target Recruit Count
- 2202
- Registration Number
- NCT05586971
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธAlliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States
๐บ๐ธSyed Research Consultants, LLC, Sheffield, Alabama, United States
Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189
- First Posted Date
- 2011-05-27
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 129
- Registration Number
- NCT01361646
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath